Quotient Sciences, a drug development services organization, has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
The acquisition further supports the growth of Quotient’s Translational Pharmaceutics platform, following the acquisitions of SeaView Research and QS Pharma in February 2017
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s services span from the characterization and optimization of drug substance physical forms, to the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply.
“The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.” said Mark Egerton, chief executive officer of Quotient Sciences.